During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.